Biggest News Aggregation in the World
📰 Allogeneic News

Page 7 - Allogeneic News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.

Priothera - FDA and EMA Grant Orphan Drug Designation to mocravimod for the treatment of Acute Myeloid Leukemia (AML) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT)

- Mocravimod is being developed as a potential best-in-class adjunctive and maintenance therapy to enhance the curative potential of HSCT for AML patients - A global registration-enabling
Frazer Hall United States Florent Gros Kostenloser Wertpapierhandel Sylvie Berrebi Prnewswire Priothera

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)

SOUTH SAN FRANCISCO - Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer... | December 6, 2021
United States South San Francisco Thousand Oaks Eric Hyllengren Atara Biotherapeutics Inc Compensation Committee Of Atara Board Directors

EMA to review Atara's MAA submission for allogeneic T-cell therapy: 'A watershed moment for the field'

The EMA has validated Atara Biotherapeutics' Marketing Authorization Application (MAA) for tabelecleucel (tab-cel), the first time an off-the-shelf allogeneic T-cell therapy will be evaluated by any regulatory agency in the world.
United States San Francisco Pierre Fabre Jakob Dupont American Society Of Hematology Drug Administration

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting

Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomasSINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics
United States Baylor College Of Medicine Malcolm Brenner Kostenloser Wertpapierhandel Sairah Ahmed Allogeneic Vsts

Takeda Pharmaceutical Company Limited: Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic ?dT Cell Therapies Addressing Solid Tumors

Acquisition expands Takeda's immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging gamma-delta T cells for the potential treatment of solid tumors and hematological
United States United Kingdom City Of Sarah Jeffery Christopher Arendt Chris Stamm

GammaDelta Therapeutics Receives FDA Clearance of IND Application for GDX012, a Novel Allogeneic Variable Delta 1 Gamma-delta T Cell Cancer Therapy

First-in-human clinical study for Acute Myeloid Leukaemia expected to begin later in 2021 FDA also granted orphan drug designation to GDX012 for the treatment of Acute Myeloid Leukaemia GammaDelta
Michael Koslowski Kostenloser Wertpapierhandel Sarah Jeffery Paolo Paoletti Chris Arendt Zyme Communications

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Positive, Topline Data from Ongoing Phase 1 Trial of Allogeneic, Off-the-Shelf Cell Therapy, in Patients with Relapsed or Refractory CD30-Positive Lymphoma

(0) Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021 BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24 th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021). The presentation at ASGCT 2021 will highlight data from six patients tre...
United States Malcolm Brenner Ingrid Mezo Johanna Bennett Carlos Ramos Dave Schemelia

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science